Literature DB >> 25582300

Down-regulation of C/EBP homologous protein (CHOP) expression in gastric cardia adenocarcinoma: Their relationship with clinicopathological parameters and prognostic significance.

Xiao-Juan Zhu1, She-Gan Gao2, San-Qiang Li3, Zhen-Guo Shi1, Zhi-Kun Ma1, Shan-Shan Zhu3, Xiao-Shan Feng1.   

Abstract

OBJECTIVE: C/EBP homologous protein (CHOP) is a multi-functional protein involved in the apoptosis pathway of endoplasmic reticulum stress (ERS) and is related to cancer progression. The purpose of this study was to assess CHOP expression as a prognostic biomarker in gastric cardia adenocarcinoma (GCA).
METHODS: The levels of CHOP mRNA and protein in GCA and matched adjacent non-cancerous tissues were evaluated by quantitative real-time-polymerase chain reaction (qRT-PCR) and western blot. Furthermore, the CHOP protein expression and localization were examined by immunohistochemistry in GCA and corresponding adjacent non-cancerous tissues, gastritis and normal cardiac tissues. The association of CHOP expression with clinical pathological parameters and prognosis of GCA patients was statistically analyzed.
RESULTS: Compared with adjacent non-cancerous tissues, the CHOP was down-regulated at mRNA and protein levels in GCA (P<0.01). In addition, immunohistochemistry analysis showed that CHOP positivity was lower in GCA than that in paired adjacent non-cancerous tissues, gastritis and normal tissues (P<0.01). CHOP expression rate gradually decreased with an increase in clinical stage, tumor differentiation and lymph node metastasis of GCA (P<0.05). Kaplan-Meier survival analysis revealed that low expression of CHOP correlated with poor prognosis of GCA patients. Moreover, univariate and multivariate analyses showed that CHOP was an independent prognostic marker for overall survival of GCA patients.
CONCLUSIONS: Our results suggest that low CHOP expression predicts poor prognosis of GCA patients, and CHOP may be potentially a prognostic biomarker for GCA.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25582300     DOI: 10.1016/j.clinre.2014.11.010

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  4 in total

1.  CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma.

Authors:  Jing Wei; Guanzhen Yu; Genbao Shao; Aiqin Sun; Miao Chen; Wannian Yang; Qiong Lin
Journal:  Oncotarget       Date:  2016-05-24

2.  Protective effect of miR378* on doxorubicin-induced cardiomyocyte injury via calumenin.

Authors:  Yu Wang; Xiaoxue Cui; Yilin Wang; Yao Fu; Xin Guo; Jie Long; Chengxi Wei; Ming Zhao
Journal:  J Cell Physiol       Date:  2018-04-17       Impact factor: 6.384

3.  The Hippo signaling effector WWTR1 is a metastatic biomarker of gastric cardia adenocarcinoma.

Authors:  Jing Wei; Lincui Wang; Jun Zhu; Aiqin Sun; Guanzhen Yu; Miao Chen; Pan Huang; Hanqing Liu; Genbao Shao; Wannian Yang; Qiong Lin
Journal:  Cancer Cell Int       Date:  2019-03-29       Impact factor: 5.722

4.  Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma.

Authors:  Soma Samanta; Shuzo Tamura; Louis Dubeau; Paulette Mhawech-Fauceglia; Yohei Miyagi; Hisamori Kato; Rich Lieberman; Ronald J Buckanovich; Yvonne G Lin; Nouri Neamati
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.